Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015695 (
fatty liver
)
13,941
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Homo sapienslongevity assurance homolog 2 of yeast LAG1 (
LASS2
) is expressed mostly in human liver. Here, we explored roles of
LASS2
in pathogenesis of
hepatic steatosis
. Hepatocyte-specific
LASS2
knockout (
LASS2
-/-
) mice were generated using Cre-LoxP system.
LASS2
-/-
and wild-type (WT) mice were fed with chow or high-fat diet (HFD). We found
LASS2
-/-
mice were resistant to HFD-induced
hepatic steatosis
and insulin resistance. In HFD-fed mice,
LASS2
deficiency significantly inhibited p38 MAPK and ERK1/ERK2 signaling in mouse liver. This effect was mediated by a significant increase of V-ATPase activity and a decrease of ROS level. We also observed that elevated expression of
LASS2
in mouse hepatocyte cell line AML12 obviously decreased V-ATPase activity and increased ROS level by activation of p38 MAPK and ERK1/ERK2 signaling. Our findings indicate that
LASS2
plays an important role in the pathogenesis of diet-induced
hepatic steatosis
and is a potential novel target for prevention and intervention of liver diseases.
...
PMID:Hepatocyte-specific deletion of LASS2 protects against diet-induced hepatic steatosis and insulin resistance. 2962 28